Given the ineffectiveness of screening for ovarian cancer, prophylactic risk-reducing salpingo-oophorectomy (RRSO) is recommended between the ages of 35 and 40 for BRCA1 carriers and between the ages of 40 and 45 for BRCA2 carriers (NCCN 2023). The gene discussed is BRCA2; the disease is ovarian carcinoma.